At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
Penguin Cold Capsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
In Brief
A clinical study evaluating Penguin Cold Caps for Breast Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The goal of this study is to estimate the efficacy of Penguin cold caps in preventing or reducing hair loss in patients receiving (neo)adjuvant chemotherapy (one of four common regimens) for early stage breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsMedical Specialties of California
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedSep 2017
Primary CompletionAug 2021
TodayJul 2026
First PostedSep 20, 2017
Enrollment StartAug 24, 2017
Primary CompletionAug 19, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.8 years ago
Interventions
Penguin Cold Capsdevice
Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.